{"brief_title": "Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).", "brief_summary": "This study will examine the viral kinetics and pharmacokinetics of Pegasys plus ribavirin and PEG-Intron plus ribavirin in interferon-naive patients with CHC. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.", "condition": ["Hepatitis C, Chronic"], "intervention_type": ["Drug", "Drug", "Drug", "Drug"], "intervention_name": ["Ribavirin", "Peginterferon alfa-2b (PEG-Intron)", "Ribavirin", "Peginterferon alfa-2a [Pegasys]"], "description": ["1000/1200mg/day po", "1.5 micrograms/kg sc weekly", "1000/1200mg/day po", "180 micrograms sc weekly"], "arm_group_label": ["Peginterferon Alfa-2a + Ribavirin", "Peginterferon Alfa-2b + Ribavirin", "Peginterferon Alfa-2b + Ribavirin", "Peginterferon Alfa-2a + Ribavirin"], "other_name": ["Copegus", "Rebetol"], "criteria": "Inclusion Criteria: - adult patients at least 18 years of age - CHC infection, genotype 1 - use of 2 forms of contraception during study in both men and women Exclusion Criteria: - previous systemic therapy with anti-viral, anti-neoplastic, or immunomodulatory agents - medical condition associated with chronic liver disease (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure) - decompensated liver disease - women who are pregnant or breastfeeding", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Hepatitis", "Hepatitis A", "Hepatitis C", "Hepatitis, Chronic", "Hepatitis C, Chronic", "Interferons", "Ribavirin", "Peginterferon alfa-2b", "Interferon-alpha", "Peginterferon alfa-2a"], "id": "NCT00087607"}